These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 23469252)

  • 1. Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up.
    Ulla M; Bonny JM; Ouchchane L; Rieu I; Claise B; Durif F
    PLoS One; 2013; 8(3):e57904. PubMed ID: 23469252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal midbrain changes in early Parkinson's disease: iron content estimated from R2*/MRI.
    Wieler M; Gee M; Martin WR
    Parkinsonism Relat Disord; 2015 Mar; 21(3):179-83. PubMed ID: 25534153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients.
    Du G; Lewis MM; Sica C; He L; Connor JR; Kong L; Mailman RB; Huang X
    Mov Disord; 2018 Sep; 33(9):1423-1431. PubMed ID: 29756399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRI assessment of basal ganglia iron deposition in Parkinson's disease.
    Wallis LI; Paley MN; Graham JM; Grünewald RA; Wignall EL; Joy HM; Griffiths PD
    J Magn Reson Imaging; 2008 Nov; 28(5):1061-7. PubMed ID: 18972346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ventral posterior substantia nigra iron increases over 3 years in Parkinson's disease.
    Bergsland N; Zivadinov R; Schweser F; Hagemeier J; Lichter D; Guttuso T
    Mov Disord; 2019 Jul; 34(7):1006-1013. PubMed ID: 31180615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of striatonigral connectivity using probabilistic tractography in Parkinson's disease.
    Theisen F; Leda R; Pozorski V; Oh JM; Adluru N; Wong R; Okonkwo O; Dean DC; Bendlin BB; Johnson SC; Alexander AL; Gallagher CL
    Neuroimage Clin; 2017; 16():557-563. PubMed ID: 28971007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential of Diffusion Tensor Imaging and Relaxometry for the Detection of Specific Pathological Alterations in Parkinson's Disease (PD).
    Esterhammer R; Seppi K; Reiter E; Pinter B; Mueller C; Kremser C; Zitzelsberger T; Nocker M; Scherfler C; Poewe W; Schocke M
    PLoS One; 2015; 10(12):e0145493. PubMed ID: 26713760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron and neuromelanin imaging in basal ganglia circuitry in Parkinson's disease with freezing of gait.
    Zhang Y; Zhang C; Wang X; Liu Y; Jin Z; Haacke EM; He N; Li D; Yan F
    Magn Reson Imaging; 2024 Sep; 111():229-236. PubMed ID: 38777243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease.
    Gorell JM; Ordidge RJ; Brown GG; Deniau JC; Buderer NM; Helpern JA
    Neurology; 1995 Jun; 45(6):1138-43. PubMed ID: 7783878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Freezing of gait in early Parkinson's disease: Nigral iron content estimated from magnetic resonance imaging.
    Wieler M; Gee M; Camicioli R; Martin WR
    J Neurol Sci; 2016 Feb; 361():87-91. PubMed ID: 26810522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Region-specific disturbed iron distribution in early idiopathic Parkinson's disease measured by quantitative susceptibility mapping.
    He N; Ling H; Ding B; Huang J; Zhang Y; Zhang Z; Liu C; Chen K; Yan F
    Hum Brain Mapp; 2015 Nov; 36(11):4407-20. PubMed ID: 26249218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased iron in the substantia nigra pars compacta identifies patients with early Parkinson'sdisease: A 3T and 7T MRI study.
    Alushaj E; Handfield-Jones N; Kuurstra A; Morava A; Menon RS; Owen AM; Sharma M; Khan AR; MacDonald PA
    Neuroimage Clin; 2024; 41():103577. PubMed ID: 38377722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson's Disease Stages?
    Hopes L; Grolez G; Moreau C; Lopes R; Ryckewaert G; Carrière N; Auger F; Laloux C; Petrault M; Devedjian JC; Bordet R; Defebvre L; Jissendi P; Delmaire C; Devos D
    PLoS One; 2016; 11(4):e0147947. PubMed ID: 27035571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson's disease.
    Geng DY; Li YX; Zee CS
    Neurosurgery; 2006 Feb; 58(2):256-62; discussion 256-62. PubMed ID: 16462479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative Susceptibility Mapping in Parkinson's Disease.
    Langkammer C; Pirpamer L; Seiler S; Deistung A; Schweser F; Franthal S; Homayoon N; Katschnig-Winter P; Koegl-Wallner M; Pendl T; Stoegerer EM; Wenzel K; Fazekas F; Ropele S; Reichenbach JR; Schmidt R; Schwingenschuh P
    PLoS One; 2016; 11(9):e0162460. PubMed ID: 27598250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of QSM over R2* in assessment of parkinson's disease - A systematic review.
    Saikiran P;
    Neurol India; 2020; 68(2):278-281. PubMed ID: 32415005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence.
    Graham JM; Paley MN; Grünewald RA; Hoggard N; Griffiths PD
    Brain; 2000 Dec; 123 Pt 12():2423-31. PubMed ID: 11099445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased iron-deposition in lateral-ventral substantia nigra pars compacta: A promising neuroimaging marker for Parkinson's disease.
    He N; Langley J; Huddleston DE; Chen S; Huang P; Ling H; Yan F; Hu X
    Neuroimage Clin; 2020; 28():102391. PubMed ID: 32889398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson's disease.
    Ryvlin P; Broussolle E; Piollet H; Viallet F; Khalfallah Y; Chazot G
    Arch Neurol; 1995 Jun; 52(6):583-8. PubMed ID: 7763206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extra-basal ganglia iron content and non-motor symptoms in drug-naïve, early Parkinson's disease.
    Kim M; Yoo S; Kim D; Cho JW; Kim JS; Ahn JH; Mun JK; Choi I; Lee SK; Youn J
    Neurol Sci; 2021 Dec; 42(12):5297-5304. PubMed ID: 33860863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.